Abstract
Sexual dysfunctions (SD) are adverse effects of common drug therapies that have rarely been considered in investigations so far. Possibly it is barely known that many widespread and frequently prescribed medications and drug therapies can have significant impact on vascular and nerval processes as well as on endocrinologic and psychoneuroendocrinologic systems and therefore can influence sexual functions. Impotence and disorders of the erectile function can mainly be caused by antidopaminergic mechanisms, whereas ejaculatory disorders and anorgasmia often can be explained by antiserotoninergic effects. Anticholinergic and adrenoloytic agents can also cause a particular impairment of erectile functions. The following considerations will show that the detection and treatment of SD (also in women!) should be given much more attention since drug-induced SDs occur predominantly in indications where a SD itself can be a symptom of the disease.
Similar content being viewed by others
References
Giuliano F, Allard J (2001) Dopamine and male sexual function. Eur Urol 40:601–608
Papatsoris AG, Korantzopoulos PG (2006) Hypertension, antihypertensive therapy and erectile dysfunction. Angiology 57:47–52
Stevenson JG, Umstead GS (1984) Sexual dysfunction due to antihypertensive agents. Drug Intell Clin Pharm 18:113–121
Chang SW, Fine R, Siegel D (1991) The impact of diuretic therapy on reported sexual function. Arch Intern Med 151:2402–2408
Loriaux DL, Menard R, Taylor A (1976) Spironolactone and endocrine dysfunction. Ann Intern Med 85:630–636
Smith PJ, Talbert RL (1986) Sexual dysfunction with antihypertensive and antipsychotic agents. Clin Pharm 5:373–384
Kolodny RC (1987) Effects of alpha-methyldopa on male sexual function. Sex Disabil 1:223–227
Newman RJ, Salerno HR (1974) Sexual dysfunction due to methyldopa. Br Med J 4:106
Bansal S (1988) Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension 12:1–10
Della Chiesa A, Pfiffner D, Meier B (2003) Sexual activity in hypertensive men. J Hum Hypertens 17:515–521
Ferrario CM, Levy P (2002) Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 4:424–432
Speel TGW, Kiemeney LA, Thien T, Smits P, Meuleman EJ (2005) Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. J Sex Med 2:207
Giraldi AG, Victor J (2002) Female sexual dysfunction as adverse effect of pharmacological treatment. Ugeskr Laeger 164:4757–4760
Brindis RG, Kloner RA (2003) Sildenafil in patients with cardiovascular disease. Am J Cardiol 92(Suppl.):26–36
Kloner RA, Mitchell M, Emmick JT (2003) Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 92(Suppl.):47–57
Aranda P, Ruilope LM, Calvo C (2004) Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 17:139–145
McLaughlin T, Harnett J, Burhani S, Scott B (2005) Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther 12:605–611
Weiss RJ (1991) Effects of antihypertensive agents on sexual function. Am Fam Physician 44:2075–2082
van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66:287–301
Clayton AH, Montejo AL (2006) Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67(Suppl. 6):33–37
Rosen RC, Marin H (2003) Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 64:5–10
Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ (2005) Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 66:686–692
Waldinger MD, Zwinderman AH, Olivier B (2003) Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol 23:467–470
Michael A, Andrews S (2002) Paroxetine-induced vaginal anaesthesia. Pharmacopsychiatry 35:150–151
Capasso R, Borrelli F, Montanaro V, Altieri V, Capasso F, Izzo AA (2005) Effects of the antidepressant St. John’s wort (Hypericum perforatum) on rat and human vas deferens contractility. J Urol 173:2194–2197
Worthington JJ 3rd, Peters PM (2003) Treatment of antidepressant-induced sexual dysfunction. Drugs Today 39:887–896
Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, Stecher VJ (2006) Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 67:240–246
Khawaja MY (2005) Sexual dysfunction in male patients taking antipsychotics. J Ayub Med Coll Abbottabad 17:73–75
Higgins A, Barker P, Begley CM (2005) Neuroleptic medication and sexuality: the forgotten aspect of education and care. J Psychiatr Ment Health Nurs 12:439–446
Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577–588
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stadler, T., Bader, M., Ückert, S. et al. Adverse effects of drug therapies on male and female sexual function. World J Urol 24, 623–629 (2006). https://doi.org/10.1007/s00345-006-0136-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-006-0136-5